Randomized, double-blind, placebo-controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in patients with Parkinson's Disease

  • Bertram, Kelly (Primary Chief Investigator (PCI))
  • Kerris, Jarrod, Alfred Health (Project Manager)

Project: Research

Project Details

Effective start/end date1/06/2131/12/23


  • Parkinson's Disease
  • pharmacodynamics
  • Pharmacokinetics
  • Clinical trial